Veligrotug

在医药研发的残酷战场上，有时候“及格”就是“平庸”，而“平庸”等同于“出局”。今天，医药圈的一场“地震”再次印证了这个真理：Viridian旗下的明星新药三期临床虽然成功了，但投资人却选择疯狂出逃。这背后，究竟是市场的偏见，还是这款“Tepezza挑战者”真的命不久矣？ 01 黑色星期一：临床成功后的“大跳水” 2026年3月30日，对于Viridian Therapeutics的股东来说，原本应该是开香槟庆祝的日子。 公司正式宣布，其用于治疗甲状腺眼病（TED）的第二款重磅抗体药物——elegrobart，在名为REVEAL-1的关键三期临床试验中大获全胜。各项指标均达到主要终点，数据看起来似乎无可挑剔。 然而，二级市场的反应却像一记响亮的耳光。 美股周一开盘，Viridian的股价应声暴跌33%，直接从上周五的27.39美元滑落至18.31美元。这不仅是财富的缩水，更是市场信心的一场雪崩。 为什么一份“成功”的临床报告，会引发一场惨烈的抛售？ 答案藏在数据背后的“暗淡之光”里。02 跨时空对决：比不过“老大哥”，也卷不赢“同门师兄” 医药界有一条不成文的潜规则：如果你的后来者不能在疗效上碾压先行者，那么你存在的意义就只剩下了“价格战”。 Viridian这次面临的，正是这种尴尬的局面。第一道坎：难以逾越的Tepezza 目前TED市场的霸主是安进（Amgen）的Tepezza。这是一款年销售额高达20亿美元的“印钞机”。 elegrobart的表现： 在REVEAL-1研究中，每月给药组的突眼缓解率（PRR）为54%。 Tepezza的纪录： 此前安进的临床数据显示其缓解率为71%左右。 即便剔除安慰剂效应，elegrobart的安慰剂校正后PRR仅为36%，远低于投资者预期的50%红线，更没能触及Tepezza曾经创下的51%校正后战绩。第二道坎：同门内卷的尴尬 更让投资者心凉的是，Viridian自家还有另一款在研药物veligrotug。 veligrotug的缓解率高达70%。 相比之下，旨在通过延长半衰期来优化体验的elegrobart，疗效却出现了明显的“缩水”。 对于机构投资者而言，逻辑很简单：既然你家里已经有一个“学霸”哥哥（veligrotug）了，为什么还要给这个“成绩中庸”的弟弟（elegrobart）溢价？ 03 体验升级：皮下注射 vs 静脉输注，谁才是真痛点？ Viridian首席执行官Steve Mahoney在发布会上极力试图挽回局势。他的核心论点是：“我们不仅看疗效，我们还看疗程。” 目前，安进的Tepezza需要进行8次静脉输注，这意味着患者必须频繁往返医院，挂水数小时。而elegrobart主打的是皮下注射，甚至具备“居家自给”的潜力。 “我们相信，elegrobart作为一种可以居家自给的治疗方案，如果获得批准，将有潜力显著扩大市场规模。” —— Steve Mahoney 这是一个性感的故事，但投资者买账吗？ 杰富瑞（Jefferies）的分析师泼了一盆冷水：虽然皮下注射更方便，但如果疗效差了一大截，医生在面对可能导致失明的眼疾患者时，真的会为了“少跑两趟医院”而牺牲复原的概率吗？这场关于“商业可行性”的激烈辩论，正是股价暴跌的导火索。04 听力损伤阴影：IGF-1R类药物的“阿喀琉斯之踵” 除了疗效不及预期，安全性数据也让市场捏了一把汗。 作为抗IGF-1R类药物，听力损伤一直是绕不开的副作用。在这次试验中： 每月给药组的安慰剂校正后听力受损率为11.3%。 而每八周给药组的这一数据仅为2.3%。 虽然绝大多数不良反应被描述为“轻微”，但在这个竞争极其激烈的赛道上，任何安全性的微小瑕疵都会被放大成巨大的商业风险。05 下一站：是绝地反击，还是从此沉沦？ 尽管遭遇资本市场的“倒戈”，Viridian并未打算就此认输。 目前的战局依然有三个关键节点值得关注： veligrotug的审评： FDA预计将在今年6月30日前决定是否批准Viridian的第一款药物veligrotug。如果过审，将为公司注入强心针。 第二项三期临床： elegrobart针对“慢性TED”的另一项三期临床试验（REVEAL-2）结果预计将在今年第二季度公布。 正式申报： 公司计划在2027年第一季度向FDA正式提交elegrobart的上市申请。 06 结语：医药创新的“幸存者偏差” Viridian的遭遇，是现代生物医药研发的一个缩影。在“Me-better”甚至“Best-in-class”成为标配的今天，“Me-too”药物的生存空间正在被无限压缩。 创新药不再仅仅是科学的博弈，更是商业效率的决斗。 对于投资者来说，这33%的跌幅是一次惨痛的提醒：在医药领域，不仅要看药能不能做出来，更要看药能不能卖出去。如果一种新药只能提供“聊胜于无”的便利，而丢掉了“硬核”的疗效，那么它的商业价值可能远比ppt上画的要单薄。 Viridian能否靠接下来的慢性TED数据翻盘？还是会沦为安进Tepezza成功路上的又一块垫脚石？让我们拭目以待。 你怎么看这次Viridian的暴跌？你认为“注射更方便”能弥补“效果打折扣”吗？ 欢迎在评论区留下你的评论。高质量观点，我们会精选置顶。 我们将持续输出： 洞察行业变局，预判未来先机。 我们持续深耕医疗健康赛道，为您提供： 深度解读： 穿透表象，还原商业底层逻辑。 标的拆解： 拆解并购核心，寻找估值锚点。 趋势研判： 捕捉投融资风向，预警行业巨震。 把复杂问题，讲清楚。 #Viridian #安进 #Amgen #Tepezza #甲状腺眼病 #TED #眼科药王 #Biotech #医药研发 #临床三期 #生物医药投资 #创新药内卷 👇 访问网站：https://www.briinsight.com 了解更多👇 👇 商务合作与咨询，敬请扫描二维码 👇 生物医药前沿洞察｜职业成长加速器聚焦创新药、制剂技术、CDMO、AI药物研发等领域的最新突破；专注生物医药研发、注册申报、临床进展与市场趋势解析；汇聚业内声音、人才资讯与实战经验，打造最具价值的行业交流平台。 👇 星标 Briinsight，轻松不迷路👇 👇 更多精彩内容，敬请关注“Briinsight” 👇 AAD-26 观察 | 40亿美元豪赌兑现！武田TYK2挑战BMS、强生：谁才是口服银屑病市场的“终结者”？ 中国CXO逆天改命！被美国“点名”整整两年，药明生物竟反手掏出一份创纪录成绩单？ 两周狂飙 50 亿！刚买下Synnovation 的乳腺癌新星，诺华再砸 20 亿闪电截胡“过敏药王”接班人Excellergy：谁会是下周的目标？ 突破“血脑屏障”！FDA今日批准Denali划时代新药：一场长达20年的极限营救，医药投资的天变了！

Jefferies analysts predicted “fierce investor debate on commercial feasibility” based on the drug’s failure to beat Tepezza based on a cross-trial comparison.\n Not content with lining up one potential rival to Amgen’s Tepezza, Viridian Therapeutics has scored a phase 3 win for another thyroid eye disease (TED) prospect. But the candidate\'s inability to meet investors’ expectations has cast a shadow over the results.Viridian evaluated the anti-IGF-1R antibody elegrobart in a late-stage study of 132 patients with TED. Patients received the injected treatment every four weeks or every eight weeks, or placebo.The study’s primary endpoint was the proptosis responder rate (PRR)—the proportion of people who experienced at least a 2 mm reduction in bulging eye—among participants on the monthly dosing regimen at week 24. The study hit this endpoint, demonstrating a responder rate of 54% compared to 18% for the placebo cohort, according to a March 30 release.Among the cohort who were dosed every eight weeks, the PRR was 63%.On the secondary endpoint of the mean change in proptosis at baseline among the monthly dosing cohort, Viridian reported a mean reduction of 2.33 mm compared to 0.81 mm in the placebo group.Meanwhile, Viridian reported the complete resolution of diplopia, the medical term for double vision, in 51% of patients on monthly elegrobart, compared with 16% of their peers in the placebo group. Viridian CEO Steve Mahoney touted this morning’s results as the “largest pivotal clinical trial conducted in active TED to date.”“REVEAL-1 met its primary endpoint with high statistical significance,” Mahoney continued. “Elegrobart treatment drove robust proptosis responses in a treatment regimen comprised of as few as three subcutaneous doses.”Amgen’s Tepezza is already on the market for TED, but Viridian is hoping that it can gain an edge because elegrobart is injected rather than administered as an intravenous infusion.“Currently, the only marketed treatment for TED requires eight intravenous infusions and, despite low market penetration, annualized in 2025 to approximately $2 billion in revenues,” Mahoney said in the release. “We believe there is a significant opportunity with subcutaneous elegrobart in TED, including the potential to expand the market as an at-home and self-administered treatment option, if approved.” While Jefferies analysts acknowledged elegrobart hit the trial’s endpoint this morning, they predicted “fierce investor debate on commercial feasibility” based on the drug’s inability to beat Tepezza in a cross-trial comparison. At 36%, elegrobart’s placebo-adjusted PRR was below the 50% bar expected by investors and didn’t reach the 51% seen in a trial of Amgen’s blockbuster, the analysts pointed out in a March 30 note.Elegrobart’s objective PRR of 54% also fell below the 70% seen by Viridian’s veligrotug, another Tepezza-rivalling anti-IGF-1R antibody. Elegrobart has the same binding domain as veligrotug and was engineered to have a longer half-life.The FDA is due to decide on whether to approve veligrotug for TED by June 30.This uncertainty of whether elegrobart can take on Tepezza in a fair fight was reflected in investors’ reaction this morning, with Viridian’s stock opening down 33% at $18.31 in pre-market trading Monday from a Friday closing price of $27.39.Evercore ISI analysts were more forgiving, however, suggesting today’s readout “meets our base case,” although they acknowledged that the absolute PRR was on the “low end” of their expected range.When it came to safety, Viridian said elegrobart was generally well-tolerated with “adverse events generally expected from the anti-IGF-1R class, the vast majority of which were mild.” Placebo-adjusted rates of hearing impairment—which has been tied to anti-IGFR drugs—were 11.3% in the monthly dosing cohort and 2.3% in those dosed every eight weeks.The Massachusetts-based biotech is running another phase 3 trial of elegrobart in chronic TED, with a readout due in the second quarter. The company’s plan is to submit an approval filing for the drug with the FDA in the first quarter of next year.